Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:

NCT ID: NCT04093947 Not yet recruiting - Obesity Clinical Trials

Characteristics of Subjects With Overweight or Obesity at the Onset of Hypertension

Start date: October 1, 2019
Phase:
Study type: Observational

The study aims to investigate the characteristics of subjects with hypertension at onset among a cohort of apparently healthy subjects, with overweight or obesity (BMI ≥ 25 Kg / m2), and free of any drug treatment at the baseline. The evaluation includes anthropometric (weight, height, BMI, waist circumference), haematochemical (hormones, metabolic and routine) parameters and the screening for hypertension with ABPM. The diagnosis of hypertension is made in accordance with the 2017 guidelines of the American College of Cardiology / American Heart Association ACC / AHA.

NCT ID: NCT04083729 Not yet recruiting - Clinical trials for Pulmonary Hypertension

Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy

Start date: September 2019
Phase: N/A
Study type: Interventional

To identify clinical, echocardiographic, and hemodynamic parameters which can predict persistent PH after PMC, and also to determine the impact of persistent PH on the clinical outcomes.

NCT ID: NCT04082091 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention

SELECT
Start date: September 2019
Phase:
Study type: Observational

We will evaluate an e_Prescription intervention can be integrated into an electronic screening program, which together exploit: (i) reach - the adult population has 100% mobile phone ownership and 92% internet national coverage; and (ii) behavioral change - the intervention can teach verbally and visually, thus bypassing literacy challenges, to allow simple, low-cost, repetition messaging for habit reinforcement. Uptake of the program through the various stages will be evaluated in ~2000 adults of a large representative suburban district of Karachi: As well as before-and-after physiological measures, including blood pressure (BP) and blood glucose, a random sample of 30-40 participants will be invited for interview to assess success and failure of the program. This is a pragmatic feasibility intervention implementation study.

NCT ID: NCT04078711 Not yet recruiting - Hypertension Clinical Trials

Chinese Medicine Treat for Hypertensive Renal Injury

CHAIR
Start date: September 10, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates whether the traditional chinese medicine (Qianyangyuyin formula) could prevent and treat early renal injury in patients with hypertension and microalbuminuria (defined as a urinary albumin to creatinine ratio between 30 and 300 mg/g) based on standard antihypertensive treatment.

NCT ID: NCT04064281 Not yet recruiting - Hypertension Clinical Trials

The Healthy Cantonese Diet on Cardiometabolic Syndrome

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

The DASH diet (Dietary Approaches to Stop Hypertension) have been proven to lower risk of cardiovascular diseases. But the DASH diet is inconsistent with Chinese dietary pattern. In this study, based on the typical Cantonese diet, the healthy Cantonese diet is developed according to the DASH diet and the balanced dietary pattern of the Chinese Dietary Guidelines 2016. The randomized control trial is designed to investigate whether the healthy Cantonese diet has benefit to blood pressure, blood lipid, blood glucose and other cardiometabolic biomarkers among adults with cardiometabolic syndrome in Guangdong, China.

NCT ID: NCT04062890 Not yet recruiting - Hypertension Clinical Trials

Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance

Start date: December 15, 2019
Phase: Phase 2
Study type: Interventional

50% of Arizonans are diabetic or pre-diabetic resulting in $6.4 billion in health care and productivity costs. The severity and incidence of Type 2 Diabetes Mellitus (T2DM) is directly related to the hepatic lipid concentration. The degree of hepatic lipid accumulation is communicated by the hepatic vagal afferent nerve (HVAN) to regulate pancreatic insulin secretion and whole body insulin sensitivity. We have shown that obesity enhances expression of GABA-Transaminase (GABA-T) decreasing hepatic release of the excitatory neurotransmitter, aspartate, and increasing release of the inhibitor neurotransmitter, GABA. This enhanced inhibitory tone decreases hepatic vagal afferent nerve activity, increasing pancreatic insulin release and decreasing skeletal muscle glucose clearance/insulin sensitivity. Pharmacological inhibition of GABA-T robustly improves glucose homeostasis in diet induced obese mice. We propose 2 clinical objectives that will test the effect of GABA-T inhibition on glucose tolerance and insulin sensitivity in obese, hyperglycemic, hyperinsulinemic patients.

NCT ID: NCT04055285 Not yet recruiting - Atrial Fibrillation Clinical Trials

Effect of Renal Denervation on Atrial Fibrillation

ERDAF
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The purpose of the ERDAF study (Effect of Renal Denervation on Atrial Fibrillation) is to evaluate the renal sympathetic denervation in patients with resistant arterial hypertension and symptomatic paroxysmal or persistent atrial fibrillation(AF) in order to show if there is a reduction in the AF-related symptoms, the AF recurrence rate, and the total burden (symptomatic and/or asymptomatic) of the arrhythmia. To the best of our knowledge, ERDAF is the first randomized study, which is going to evaluate the effect of RDN [without pulmonary vein isolation (PVI)] on AF recurrence profile and AF ''burden'' using continuous long-term rhythm monitoring via ILRs for a period of 18 months. Hypothesis Renal sympathetic denervation in patients with resistant hypertension and symptomatic paroxysmal or persistent atrial fibrillation reduces AF recurrences, total AF "burden" (asymptomatic / symptomatic) and limits the AF-related symptoms.

NCT ID: NCT04035538 Not yet recruiting - Hypertension Clinical Trials

A Clinical Study to Compare the Safety and Pharmacokinetics of CKD-320 and D012

Start date: August 2019
Phase: Phase 1
Study type: Interventional

A clinical study to compare the safety and pharmacokinetics of CKD-320 and D012

NCT ID: NCT04035148 Not yet recruiting - COPD Clinical Trials

CPET in Evaluation of PH in COPD Patients

Start date: October 1, 2019
Phase:
Study type: Observational

- To evaluate the entire course of exercise during CPET in COPD patients. - To study whether CPET, PFTs and arterial blood gases could discriminate between COPD patients with and without PH. - To study whether the existence of pulmonary hypertension in COPD is related to characteristic findings in gas exchange and circulatory parameters during cardiopulmonary exercise testing (CPET).

NCT ID: NCT04025801 Not yet recruiting - Hypertension Clinical Trials

Heidelberg In Vivo Confocal Microscopy to Evaluate the Ocular Surface Disorders of Healthy and Diseased Individuals

Start date: July 31, 2019
Phase:
Study type: Observational

In vivo confocal microscopy (IVCM) has been used in clinical settings for more than 25 years, and is noninvasive, rapid and easily repeatable technique to investigate ocular surface disorders. It enables morphological and quantitative analysis of ocular surface microstructure. [1-3] As the technology advances, new IVCM machine, Heidelberg Retinal Tomograph with Rostock Corneal Module (HRT-RCM), was developed. Hardware and software modifications and acquisition techniques continue to expand the applications of the HRT-RCM for quantitative in vivo corneal imaging at the cellular level. The new software can access the corneal nerve more accurate. Here the investigators proposed this Institutional Review Board (IRB) to collect healthy persons and cases of different systematic diseases as well as etiologies of ocular surface diseases.